Article

Military Spends $84 Million on Erectile Dysfunction Drugs

The Department of Defense spent more than $84 million on erectile dysfunction medications in 2014, according to a report in Military Times. Nearly half of that, $41.6 million, was spent on Viagra, with military doctors writing nearly a million prescriptions for that drug alone last year.

Viagra

The US military is proving a mighty market for erectile dysfunction drugs.

The Department of Defense spent more than $84 million on erectile dysfunction medications in 2014, according to a report in Military Times. Nearly half of that, $41.6 million, was spent on Viagra, with military doctors writing nearly a million prescriptions for that drug alone last year.

The Defense Department also spent millions on Eli Lilly’s Cialis and Pfizer’s Revatio. The figures come from data from the Defense Health Agency.

The ED spending came to light when the conservative news website Washington Free Beacon reported that the agency had spent $504,816 on Viagra. The story inspired waves of Internet chatter, even though it turned out to be based on incomplete information. The Free Beacon’s figure came from 60 DOD contracts awarded to Cardinal Health Inc. However, those contracts represent only a small part of the Defense Department’s pharmaceutical purchases. The Military Times report included prescriptions filled through pharmacy benefits giant Express Scripts.

A study released last year by the Armed Forces Health Surveillance Center found more than 100,000 active-duty military members were diagnosed with ED between 2004 and 2013. The report found less than 1% of servicemen under age 40 were diagnosed with the condition, and in more than half of the cases the condition was attributed to psychiatric causes.

The vast majority of ED prescriptions were for non-active duty beneficiaries, which could include retired service members, and military family members.

According to Pfizer, Viagra brought in $457 million in global revenue in the fourth quarter of 2014, down about 4% slightly from the fourth quarter of 2013. The majority of those sales, $324 million, came in the US.

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Nathan D. Wong, MD, PhD: Growing Role of Lp(a) in Cardiovascular Risk Assessment | Image Credit: UC Irvine
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Laurence Sperling, MD: Multidisciplinary Strategies to Combat Obesity Epidemic | Image Credit: Emory University
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orly Vardeny, PharmD: Finerenone for Heart Failure with EF >40% in FINEARTS-HF | Image Credit: JACC Journals
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Matthew Weir, MD: Prioritizing Cardiovascular Risk in Chronic Kidney Disease | Image Credit: University of Maryland
Erin Michos, MD: HFpEF in Women and Sex-Specific Therapeutic Approaches | Image Credit: Johns Hopkins
© 2024 MJH Life Sciences

All rights reserved.